Patients struggle with lack of consistent coverage for popular weight-loss drugs
Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity treatments because a wide swath of the population could be eligible to take them, and patients have to stay on the drugs to keep the weight off.
The Trump administration, perhaps surprisingly, chose to defend the legality of the Inflation Reduction Act’s (IRA’s) drug ...
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
The drugs identified for negotiation in the second round include: Ozempic, Wegovy and other GPL-inhibitors are in high demand in the U.S. Due to that demand, Medicare covering them for diabetes ...
Insurers also ask the Trump administration, which is engaged in a sweeping campaign to eradicate anything related to ...
This will be a “pivotal year,” one expert says, for GLP-1 drugs, which are massively disrupting the benefits landscape.
The Food and Drug Administration said on Friday that there is no longer a shortage of drugs like Wegovy and Ozempic. The semaglutide known as Ozempic is intended to be used for people with diabetes.
Some workers are willing to trade vacation days or go back to the office in exchange for weight-loss drug coverage by their ...
The company's blockbuster semaglutide drugs, Wegovy for weight loss and Ozempic ... REUTERS / Reuters Another potential headwind is Medicare drug pricing negotiations. The earnings report is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback